Compugen Ltd (CGEN)
NASDAQ:CGEN

Compugen (CGEN) Stock Price & Analysis

733 Followers

CGEN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.51 - $3.57
Previous Close$0.98
Volume380.51K
Average Volume (3M)679.58K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$88.21M
Total Debt (Recent Filing)$1.98M
Price to Earnings (P/E)-2.1
Beta2.87
Next EarningsFeb 23, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-0.45
Shares Outstanding86,624,643
R-Squared0.32
Standard Deviation0.25
10 Day Avg. Volume652,466
30 Day Avg. Volume679,578
Price to Book (P/B)0.93
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside786.08% Upside
Rating ConsensusStrong Buy
Alpha-0.01
Number of Analyst Covering4


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CGEN FAQ

What was Compugen’s price range in the past 12 months?
Compugen lowest stock price was $0.51 and its highest was $3.57 in the past 12 months.
    What is Compugen’s market cap?
    Currently, no data Available
    When is Compugen’s upcoming earnings report date?
    Compugen’s upcoming earnings report date is Feb 23, 2023 which is in 15 days.
      How were Compugen’s earnings last quarter?
      Compugen released its earnings results on Nov 14, 2022. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.
        Is Compugen overvalued?
        According to Wall Street analysts Compugen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Compugen pay dividends?
          Compugen does not currently pay dividends.
          What is Compugen’s EPS estimate?
          Compugen’s EPS estimate is -$0.14.
            How many shares outstanding does Compugen have?
            Compugen has 86,624,640 shares outstanding.
              What happened to Compugen’s price movement after its last earnings report?
              Compugen reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -9.783%.
                Which hedge fund is a major shareholder of Compugen?
                Among the largest hedge funds holding Compugen’s share is ARK Investment Management LLC. It holds Compugen’s shares valued at 760K.

                  ---

                  Compugen Stock Smart Score

                  4
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -68.98%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -43.94%
                  Trailing 12-Months
                  Asset Growth
                  -18.08%
                  Trailing 12-Months
                  The Compugen stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Compugen Ltd

                  Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Quoin Pharmaceuticals
                  Bayer
                  Merck & Company
                  Cell Kinetics

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis